Why Am I Not Losing Weight on Semaglutide?

Not losing weight on semaglutide? Learn how dosage, treatment duration, nutrition, medications, health conditions, and individual response can affect your results—and when to discuss a treatment change with your provider.

WEIGHT MANAGEMENT

Sarina Helton, FNP-C, MSN, CAE-OM

10/6/20268 min read

Why Am I Not Losing Weight on Semaglutide?

Common Reasons Semaglutide May Not Be Producing the Weight Loss You Expected

Semaglutide can be highly effective for weight management, but it does not produce the same results for everyone. Some people notice reduced hunger and steady weight loss within the first few weeks. Others require several months and higher therapeutic doses before seeing a meaningful response. A smaller group experiences little or no weight loss despite appropriate treatment.

If you are taking semaglutide and the scale is not moving, it does not automatically mean you are doing something wrong. However, it does mean your treatment deserves a closer look.

How Much Weight Loss Should You Expect?

In the STEP 1 clinical trial, adults without diabetes who received semaglutide 2.4 mg weekly along with lifestyle intervention lost an average of approximately 14.9% of their starting weight over 68 weeks. This was an average—not a guarantee. Some participants lost considerably more, while others lost much less. Wilding et al., 2021

People with type 2 diabetes generally lose less weight with semaglutide. In the STEP 2 trial, adults with overweight or obesity and type 2 diabetes lost an average of approximately 9.6% over 68 weeks while receiving semaglutide 2.4 mg weekly. Davies et al., 2021

Clinical-trial results also reflect many months of treatment at or near a therapeutic dose. They should not be used to judge the medication after only a few weeks.

1. You May Still Be Taking a Starting Dose

One of the most common explanations is that treatment has not progressed far enough.

For Wegovy injections, the FDA-approved escalation schedule begins at:

0.25 mg weekly for weeks 1–4
0.5 mg weekly for weeks 5–8
1 mg weekly for weeks 9–12
1.7 mg weekly for weeks 13–16
1.7 or 2.4 mg weekly as a maintenance dose, with 2.4 mg recommended when tolerated

The lower doses are primarily used to help the body adjust and reduce gastrointestinal side effects. They are not expected to produce the medication’s full weight-loss effect. Wegovy prescribing information

Some people lose weight at 0.25 or 0.5 mg, but others do not notice a meaningful effect until they reach a higher dose.

Dose increases should still be based on tolerability and clinical appropriateness. A dose should not be increased early simply because the scale has not moved.

2. You Have Not Been Taking It Long Enough

Semaglutide is not a rapid weight-loss medication. Dose escalation alone generally takes approximately four months.

Early changes can also be inconsistent:

Hunger may improve before weight changes.
Weight may fall rapidly and then temporarily stabilize.
Constipation may temporarily increase scale weight.
Menstrual-cycle changes, sodium intake, inflammation, and fluid retention may obscure fat loss.
A single weigh-in may not reflect the overall trend.

Evaluate progress using several weeks of consistent measurements rather than one or two numbers.

3. Your Dose May Not Be What You Think It Is

This is especially important when medication is drawn from a multidose vial.

Semaglutide dosing may be expressed in:

Milligrams
Milliliters
Syringe units

These measurements are not interchangeable.

For example, “20 units” only describes the volume in the syringe. It does not identify the number of milligrams administered unless the medication concentration is also known.

Different compounded formulations can have different concentrations. Patients should confirm:

The concentration listed on the prescription label
The prescribed dose in milligrams
The corresponding volume or syringe units
That the correct syringe is being used
That the full dose is being injected as directed

Do not increase the number of syringe units based on information found online. Contact the prescribing clinic or dispensing pharmacy if the instructions are unclear.

4. Missed or Inconsistent Doses May Be Reducing the Effect

Semaglutide works best when taken consistently according to the prescribed schedule.

Weight-loss response may be reduced by:

Frequently missing doses
Taking injections at irregular intervals
Stopping and restarting treatment
Remaining at a low dose because of prolonged interruptions
Being unable to tolerate dose escalation

If multiple doses have been missed, do not automatically restart at the previous dose. Re-escalation may be necessary to reduce gastrointestinal side effects.

5. Semaglutide May Be Reducing Hunger Less Than Expected

Semaglutide generally supports weight loss by increasing fullness, decreasing hunger, and reducing energy intake. It does not directly force the body to lose weight regardless of food intake.

Consider whether you have noticed meaningful changes in:

Hunger between meals
Portion size
Feeling satisfied after eating
Food cravings
Thoughts about food
Snacking or grazing
Ability to stop eating when comfortably full

If none of these have changed after an adequate trial at a therapeutic dose, you may be experiencing a limited medication response.

6. Liquid Calories and Small, Calorie-Dense Foods Can Bypass Fullness

Some foods are easy to consume even when semaglutide is producing early fullness.

Common examples include:

Sweetened coffee drinks
Alcohol
Juice or regular soda
Creamers
Protein shakes with multiple calorie-dense additions
Nuts and nut butters
Cheese
Oils, dressings, and sauces
Frequent small snacks
Sweets eaten in small portions throughout the day

These foods are not automatically forbidden. However, small amounts can contain substantial energy without producing the same fullness as a meal containing protein, fiber, and minimally processed foods.

A short, honest review of beverages, snacks, portions, and weekend eating patterns can be more useful than following an extremely restrictive diet.

7. Reduced Hunger May Be Leading to Irregular Eating

Some patients eat very little during the day and become significantly hungrier at night. Others skip protein-containing meals, lose structure, and rely on convenient snack foods because nothing sounds appealing.

This pattern can make it difficult to meet nutritional needs and may contribute to:

Evening overeating
Fatigue
Reduced activity
Loss of lean mass
Constipation
Poor exercise recovery

The goal is not to eat as little as possible. It is to use the reduction in hunger to build a sustainable eating pattern.

8. Your Activity or Muscle Mass May Have Changed

When calorie intake decreases, the body may respond by reducing spontaneous movement. You may sit more, take fewer steps, or exercise less without realizing it.

Weight loss also includes some lean tissue unless steps are taken to preserve it. Adequate protein intake and resistance training are particularly important during treatment.

Exercise does not need to be extreme. A realistic plan may include:

Regular walking
Gradually increasing daily movement
Resistance training two or more times weekly when medically appropriate
Adequate protein and hydration
Sufficient recovery and sleep

Exercise supports health, body composition, and weight maintenance even when its immediate effect on the scale appears modest.

9. Another Medication May Be Working Against Your Weight-Loss Efforts

Some medications can increase appetite, promote fluid retention, alter glucose regulation, or contribute to weight gain. Examples may include certain:

Antipsychotics
Antidepressants
Mood stabilizers
Insulins and insulin-stimulating diabetes medications
Corticosteroids
Seizure medications
Antihistamines
Hormonal medications

Do not discontinue a necessary medication to promote weight loss. A clinician can review whether the medication may be contributing and whether a reasonable alternative exists.

10. An Underlying Health Condition May Be Contributing

Semaglutide can be effective even when other medical conditions are present, but those conditions may influence the rate of weight loss.

Potential contributors include:

Untreated or undertreated hypothyroidism
Type 2 diabetes
Polycystic ovary syndrome
Menopause-related body-composition changes
Sleep apnea
Chronic sleep deprivation
Depression or significant stress
Reduced mobility
Fluid retention
Cushing syndrome, although this is uncommon
Other endocrine or metabolic disorders

Routine testing for every possible condition is usually unnecessary. Laboratory evaluation should be guided by symptoms, medical history, physical findings, and previous results.

11. Your Starting Weight and Previous Weight Loss Matter

Percentage-based weight loss can look very different on the scale.

A 5% reduction equals:

10 pounds from a starting weight of 200 pounds
12.5 pounds from 250 pounds
15 pounds from 300 pounds

People who have already lost substantial weight may also lose more slowly as they approach a lower weight. The body adapts to weight loss through changes in hunger, energy expenditure, and other biological signals.

A slower rate does not necessarily mean treatment has stopped working.

12. You May Be Losing Fat Without Seeing an Immediate Scale Change

The scale measures more than body fat. It also reflects:

Water
Stored carbohydrate
Food in the digestive tract
Stool
Muscle
Menstrual-cycle-related fluid changes

Waist circumference, clothing fit, strength, mobility, glucose levels, blood pressure, and other metabolic measurements may provide additional information.

However, if weight and waist circumference remain unchanged for several months, it is reasonable to question whether meaningful fat loss is occurring.

13. Your Body May Simply Respond Less Strongly

Average trial results do not represent every patient.

In STEP 1, most—but not all—participants receiving semaglutide achieved at least 5% weight loss. Biological response varies because of differences in genetics, appetite regulation, diabetes status, starting weight, other medications, health conditions, adherence, and medication exposure.

True limited response or nonresponse exists. It should not automatically be blamed on willpower.

When Should Your Treatment Be Reassessed?

Consider requesting a clinical review if:

You have had little or no weight loss after an adequate trial.
You have reached a therapeutic dose but notice no reduction in hunger or portions.
Side effects prevent you from reaching or maintaining an effective dose.
You are unsure how many milligrams you are administering.
You are missing doses because of cost, shortages, or side effects.
You initially lost weight but have now reached a prolonged plateau.
You are regaining weight despite continued treatment.
Your eating pattern has become overly restrictive or nutritionally inadequate.
You have new symptoms suggesting another medical problem.

A proper reassessment may include reviewing the medication source, dose, concentration, injection technique, adherence, weight trajectory, appetite response, nutrition, activity, sleep, other medications, and relevant health conditions.

Does the Dose Always Need to Be Increased?

No.

Increasing the dose may be reasonable when:

You are still below a maintenance dose.
The current dose is well tolerated.
Hunger control remains inadequate.
Your clinician determines escalation is appropriate.

Increasing the dose may not be appropriate when:

You are already experiencing significant side effects.
You are already taking the maximum appropriate dose.
You cannot maintain adequate nutrition or hydration.
The medication has produced no meaningful appetite effect despite an adequate therapeutic trial.
Another medical or medication-related issue needs to be addressed first.

More medication is not always the correct answer.

Should You Switch to Tirzepatide?

Tirzepatide may produce greater average weight loss than semaglutide, but switching is not automatically necessary or appropriate.

Before changing treatment, determine whether semaglutide has been given a fair trial. Switching medications will not correct:

Incorrect dosing
Missed doses
Unrecognized liquid calories
A medication causing weight gain
Untreated sleep apnea
Severe sleep deprivation
An eating pattern that is not sustainable

Some patients may benefit from tirzepatide or another weight-management medication after an individualized clinical review. Insurance coverage, contraindications, side effects, medication availability, and cost also matter.

What Not to Do

If semaglutide is not producing the expected result:

Do not increase the dose without medical guidance.
Do not combine it with another GLP-1 medication.
Do not copy someone else’s syringe-unit instructions.
Do not assume severe nausea means the medication is working better.
Do not respond by starving yourself.
Do not abruptly stop medications prescribed for another medical condition.
Do not continue indefinitely without reassessing whether treatment is providing meaningful benefit.

Bottom Line

If you are not losing weight on semaglutide, the explanation may be straightforward: you may still be titrating, may not have had enough time, or may need your dose and administration reviewed.

Other patients have medical, nutritional, behavioral, or medication-related factors affecting their progress. Some people simply do not respond strongly to semaglutide.

The appropriate next step is not blame. It is a structured evaluation of:

What you are taking
How much you are taking
How consistently you are taking it
How your appetite has changed
What your weight trend shows
What other factors may be interfering
Whether continuing, adjusting, or changing treatment makes clinical sense

Ready to Start Your Weight Management Journey?

GLP-1 medications can be powerful tools, but the right medication, dose, and rate of dose escalation can be different for each person.

At Optima Vida Healthcare, weight management is individualized based on your health history, previous treatments, response to medication, side effects, goals, and long-term needs.

Treatment may include GLP-1 or other weight-management medications when medically appropriate, along with ongoing monitoring and support.

Start Your Weight Management Evaluation →

Or Visit www.ovhmed.com for more information.

Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare provider.

Medical Disclaimer

This information is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397:971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

Garvey WT, Batterham RL, Bhatta M, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nat Med. 2022;28:2083–2091. https://pubmed.ncbi.nlm.nih.gov/36216945/

U.S. Food and Drug Administration. Wegovy Prescribing Information. Revised 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf

Why Am I Not Losing Weight on Semaglutide?

Why Am I Not Losing Weight on Semaglutide?

Common Reasons Semaglutide May Not Be Producing the Weight Loss You Expected

If you are taking semaglutide and the scale is not moving, it does not automatically mean you are doing something wrong. However, it does mean your treatment deserves a closer look.

How Much Weight Loss Should You Expect?

People with type 2 diabetes generally lose less weight with semaglutide. In the STEP 2 trial, adults with overweight or obesity and type 2 diabetes lost an average of approximately 9.6% over 68 weeks while receiving semaglutide 2.4 mg weekly. Davies et al., 2021

Clinical-trial results also reflect many months of treatment at or near a therapeutic dose. They should not be used to judge the medication after only a few weeks.

1. You May Still Be Taking a Starting Dose

One of the most common explanations is that treatment has not progressed far enough.

For Wegovy injections, the FDA-approved escalation schedule begins at:

0.25 mg weekly for weeks 1–4

0.5 mg weekly for weeks 5–8

1 mg weekly for weeks 9–12

1.7 mg weekly for weeks 13–16

1.7 or 2.4 mg weekly as a maintenance dose, with 2.4 mg recommended when tolerated

The lower doses are primarily used to help the body adjust and reduce gastrointestinal side effects. They are not expected to produce the medication’s full weight-loss effect. Wegovy prescribing information

Some people lose weight at 0.25 or 0.5 mg, but others do not notice a meaningful effect until they reach a higher dose.

Dose increases should still be based on tolerability and clinical appropriateness. A dose should not be increased early simply because the scale has not moved.

2. You Have Not Been Taking It Long Enough

Semaglutide is not a rapid weight-loss medication. Dose escalation alone generally takes approximately four months.

Early changes can also be inconsistent:

Hunger may improve before weight changes.

Weight may fall rapidly and then temporarily stabilize.

Constipation may temporarily increase scale weight.

Menstrual-cycle changes, sodium intake, inflammation, and fluid retention may obscure fat loss.

A single weigh-in may not reflect the overall trend.

Evaluate progress using several weeks of consistent measurements rather than one or two numbers.

3. Your Dose May Not Be What You Think It Is

This is especially important when medication is drawn from a multidose vial.

Semaglutide dosing may be expressed in:

Milligrams

Milliliters

Syringe units

These measurements are not interchangeable.

For example, “20 units” only describes the volume in the syringe. It does not identify the number of milligrams administered unless the medication concentration is also known.

Different compounded formulations can have different concentrations. Patients should confirm:

The concentration listed on the prescription label

The prescribed dose in milligrams

The corresponding volume or syringe units

That the correct syringe is being used

That the full dose is being injected as directed

Do not increase the number of syringe units based on information found online. Contact the prescribing clinic or dispensing pharmacy if the instructions are unclear.

4. Missed or Inconsistent Doses May Be Reducing the Effect

Semaglutide works best when taken consistently according to the prescribed schedule.

Weight-loss response may be reduced by:

Frequently missing doses

Taking injections at irregular intervals

Stopping and restarting treatment

Remaining at a low dose because of prolonged interruptions

Being unable to tolerate dose escalation

If multiple doses have been missed, do not automatically restart at the previous dose. Re-escalation may be necessary to reduce gastrointestinal side effects.

5. Semaglutide May Be Reducing Hunger Less Than Expected

Semaglutide generally supports weight loss by increasing fullness, decreasing hunger, and reducing energy intake. It does not directly force the body to lose weight regardless of food intake.

Consider whether you have noticed meaningful changes in:

Hunger between meals

Portion size

Feeling satisfied after eating

Food cravings

Thoughts about food

Snacking or grazing

Ability to stop eating when comfortably full

If none of these have changed after an adequate trial at a therapeutic dose, you may be experiencing a limited medication response.

6. Liquid Calories and Small, Calorie-Dense Foods Can Bypass Fullness

Some foods are easy to consume even when semaglutide is producing early fullness.

Common examples include:

Sweetened coffee drinks

Alcohol

Juice or regular soda

Creamers

Protein shakes with multiple calorie-dense additions

Nuts and nut butters

Cheese

Oils, dressings, and sauces

Frequent small snacks

Sweets eaten in small portions throughout the day

These foods are not automatically forbidden. However, small amounts can contain substantial energy without producing the same fullness as a meal containing protein, fiber, and minimally processed foods.

A short, honest review of beverages, snacks, portions, and weekend eating patterns can be more useful than following an extremely restrictive diet.

7. Reduced Hunger May Be Leading to Irregular Eating

Some patients eat very little during the day and become significantly hungrier at night. Others skip protein-containing meals, lose structure, and rely on convenient snack foods because nothing sounds appealing.

This pattern can make it difficult to meet nutritional needs and may contribute to: